WASHINGTON, D.C. (Jan. 19, 1999) Fifty-two companies will participate in the annual CEO & Investor Conference organized by the Biotechnology Industry Organization (BIO) Feb. 24-26, 1999, in New York.
BIO's investor conference is different from most in two key respects. First, company presentations will be made by CEOs in 12 investor sessions, each one dedicated to a different disease focus or therapeutic approach. This will allow investors to evaluate complementary and competitive technologies.
Second, nine investment banks will co-sponsor the conference. They are Adams, Harkness & Hill Inc.; Hambrecht & Quist; ING Barring Furman Selz; Lehman Brothers; Piper Jaffray Inc.; Punk, Ziegel & Co.; Warburg Dillon Read; Raymond James & Associates; and Silicon Valley Bank.
Keynote speakers will be Dr. Hank McKinnell, president of Pfizer Pharmaceuticals, at the opening lunch, Wednesday, Feb. 24, and Knight Kiplinger, editor of The Kiplinger Letter and editor-in-chief of Kiplinger's Personal Finance Magazine, at lunch Thursday, Feb. 25.
The conference will be held at the New York Palace Hotel and will be open to the news media. An estimated 150 investors and 200 U.S. and international biotechnology executives are expected to attend.
In addition to the 12 investor sessions, CEOs also will participate in separate roundtable discussions on business issues, such as creative financing; how to create and sustain value from a technology platform; a CEO's roadmap from R&D to profitability; cross border financing; industry consolidation - is it the model of the future?; and how to maximize the value of your intellectual property portfolio.
Investor sessions will be 90 minutes or two hours with a maximum of four CEOs presenting in the shorter sessions and five in the longer ones. Sessions will be moderated by a banker, portfolio manager, pharmaceutical company executive or a clinician.
Below are investor session topics and presenting companies as of this date.
Wednesday, February 24
2 - 4 p.m.
Solid Tissue Tumors: New & emerging therapies
Session sponsor: Lehman Brothers
Presenting companies: Abgenix Inc., Genzyme Molecular Oncology, Genentech Inc. (invited), Geron Corp., Sugen Inc.
Drug delivery: Does the business model still work?
Session sponsor: Hambrecht & Quist
Presenting companies: Alkermes Inc., ALZA Corp. (invited), Aronex Pharmaceuticals Inc., Inhale Therapeutic Systems
Thursday, February 25
8:30 - 10 a.m.
Vaccines and women's health issues
Session sponsor: Silicon Valley Bank
Presenting companies: Biomira Inc., Corixa Corp., La Jolla Pharmaceuticals, StressGen Biotechnologies Corp.
Genomics: The next generation of drugs
Session sponsor: Warburg Dillon Read
Presenting companies: Evotec Biosystems, HumanGenome Sciences Inc., Genome Therapeutics Corp., Millennium Pharmaceuticals Inc.
10:30 - noon
Rheumatoid Arthritis: Product launches transform biotech companies
Session sponsor: Adams, Harkness & Hill
Presenting companies: Calyx Therapeutics, Cambridge Antibody Technology, Cypress Bioscience, Immunex Corp. (invited)
Pharmacogenomics: Fact or fad the dynamics of a new industry
Session sponsor: Punk Ziegel
Presenting companies: CuraGen Corp., Genset, Genaissance Pharmaceuticals, Variagenics Inc.
2 - 4 p.m.
High Throughput Screening From validated target to clinic ready compound
Session sponsor: ING Baring Furman Selz
Presenting companies: Arena Pharmaceuticals Inc., Aurora Biosciences Corp., Gene Logic Inc., LJL Biosystems Inc., Pharmacopeia Inc.
Oncology: The Strategic/Competitive Landscape
Session sponsor: Piper Jaffray
Presenting companies: Antigenics LLC, EntreMed Inc., ILEX Oncology, Onyx Pharmaceuticals
Friday, February 26
8:30 - 10 a.m.
Cardiovascular therapeutics: A heart-to-heart discussion
Session sponsor: Raymond James
Presenting companies: AVANT Immunotherapeutics, Collateral Therapeutics, CV Therapeutics
Session sponsor: SmithKline Beecham
Presenting companies: Nabi, ViroPharma Inc.,Triangle Pharmaceuticals, SCRIPTGEN Pharmaceuticals
10:30 - noon
Session sponsor: Bayer Corp.
Presenting companies: Incyte Pharmaceuticals (invited), Pangea Systems, Structural Bioinformatics (invited)
CNS or Gene Therapy
Session sponsor: TBA
Presenting companies: TBA
For media registration contact Charles Craig at BIO in Washington, D.C., at 202-962-9200, or email@example.com.